Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results
US$12 Billion RNA Deal Triggers Sector Shakeup
Preclinical Compounds Perform Better Than Existing Drugs
Research Report
Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Biotech to Fast Track Phase 3 Depression Trial
Research Report
2 Key Catalysts Ahead for Developer of Psych Drugs
Research Report
Co. Speeds Up Development of New Drug for Depression
Research Report
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report. Price Target on Psychiatric Drug Biotech Boosted 200%
Research Report
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report. US Biopharma In-Licenses 3 New Assets
Research Report
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report. Chen's High-Grade Gold, Silver Plays for Q4
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside?AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases.Cleantech Co. Advances Antimicrobial Wound Care Breakthrough
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization."Biopharma's New MASH Drug Has Two MOAs
Research Report
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report. Life Sciences Co. Reports Strong Survival Data
Research Report
OS Therapies Inc.'s (OSTX:NYSEAMERICAN) trial results are for its new immunotherapy in fully resected pulmonary metastatic osteosarcoma, noted a D. Boral Capital report. Therapeutics Company Advances Gene Therapy Breakthrough
Research Report
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval. 
Streetwise Key Charts
